A Randomized, Double-blind, Parallel, Multicenter, Placebo-controlled, Prospective Study to Evaluate the Functionality of the Flushing ASsessment Tool (FAST) in Subjects Administered Niaspan [niacin] Plus Acetylsalicylic Acid (ASA), Niaspan Plus ASA Placebo or Niaspan Placebo Plus ASA Placebo Daily for Six Weeks.

Trial Profile

A Randomized, Double-blind, Parallel, Multicenter, Placebo-controlled, Prospective Study to Evaluate the Functionality of the Flushing ASsessment Tool (FAST) in Subjects Administered Niaspan [niacin] Plus Acetylsalicylic Acid (ASA), Niaspan Plus ASA Placebo or Niaspan Placebo Plus ASA Placebo Daily for Six Weeks.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2009

At a glance

  • Drugs Aspirin; Niacin
  • Indications Dyslipidaemias; Embolism and thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 31 Aug 2009 Efficacy results presented at the Annual Congress of the European Society of Cardiology (ESC).
    • 13 Jan 2009 Planned number of patients changed from 246 to 276 as reported by ClinicalTrials.gov.
    • 13 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top